Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers


1. Chenyl Taurine Sodium
2. Tauroursodeoxycholate
3. Tauroursodeoxycholate Sodium Salt
4. Tauroursodeoxycholic Acid, (3alpha,5alpha,7alpha)-isomer
5. Tauroursodeoxycholic Acid, Monosodium Salt, (3alpha,5beta,7alpha)-isomer
6. Taurursodiol
7. Tudca
8. Ursodoxicoltaurine
1. 14605-22-2
2. Tudca
3. Ursodeoxycholyltaurine
4. Tauroursodeoxycholate
5. Taurursodiol
6. Taurolite
7. Ursodoxicoltaurine
8. Ur 906
9. Sodium Tauroursodeoxycholate
10. Tauroursodesoxycholic Acid
11. Ursodeoxy Cholic Acid
12. Taurursodiol [usan]
13. 60eux8mn5x
14. Chembl272427
15. Chebi:80774
16. Ur-906
17. Taurursodiol (usan)
18. Ursodoxicoltaurine (inn)
19. Ursodoxicoltaurine [inn]
20. N-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)-taurine
21. Tauroursodeoxycholate Sodium
22. 2-[(4r)-4-[(1s,2s,5r,7s,9s,10r,11s,14r,15r)-5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]pentanamido]ethane-1-sulfonic Acid
23. 2-{[(3alpha,5beta,7alpha,8alpha,14beta,17alpha)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethanesulfonic Acid
24. Unii-60eux8mn5x
25. N-(3alpha,7beta-dihydroxy-5beta-cholan-24-oyl)taurine
26. Mfcd00065451
27. Tuda
28. N-ursodeoxycholoyltaurine
29. Tauroursodeoxycholic Acid, Sodium Salt
30. Schembl40764
31. Gtpl4746
32. Tauroursodeoxycholic Acid;tudca
33. Dtxsid80932754
34. Ex-a730
35. 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl) Amino)ethanesulfonic Acid
36. Hms3885c19
37. Ursodoxicoltaurine [who-dd]
38. Taurine, N-(3-alpha,7-beta-dihydroxy-5-beta-cholan-24-oyl)-,
39. Zinc3914813
40. 3alpha,7beta-dihydroxy-5beta-cholan-24-oic Acid N-(2-sulfoethyl)amide
41. Bdbm50236230
42. Lmst05040015
43. S3654
44. Sodium Tauroursodeoxycholate, >=95%
45. Who 11388
46. Ccg-269687
47. Db08834
48. 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)ethanesulfonic Acid
49. Ac-34539
50. Hy-19696
51. Cs-0016289
52. T1567
53. 3alpha,7beta-dihydroxy-5beta-cholanoyltaurine
54. D11836
55. 605t222
56. A808445
57. Q7688907
58. 3,7-dihydroxy-n-(2-sulfoethyl)cholan-24-imidic Acid
59. 3.alpha.,7.beta.-dihydroxy-5.beta.-cholanoyltaurine
60. 2-[(3alpha,7beta-dihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic Acid
61. 2-{[(3alpha,5beta,7beta)-3,7-dihydroxy-24-oxocholan-24-yl]amino}ethane-1-sulfonic Acid
62. Ethanesulfonic Acid,2-[[(3a,5b,7b)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-
63. 2-((r)-4-((3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-hexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanamido)ethanesulfonic Acid
64. 2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-3,7-bis(oxidanyl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonic Acid
65. 2-[[(4r)-4-[(3r,5s,7s,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-1-oxopentyl]amino]ethanesulfonic Acid
66. Ethanesulfonic Acid, 2-(((3-alpha,5-beta,7-beta)-3,7-dihydroxy-24-oxocholan-24-yl)amino)-
| Molecular Weight | 499.7 g/mol |
|---|---|
| Molecular Formula | C26H45NO6S |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 7 |
| Exact Mass | 499.29675933 g/mol |
| Monoisotopic Mass | 499.29675933 g/mol |
| Topological Polar Surface Area | 132 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 858 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 10 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used in the treatment of cholesterol gallstones. Tauroursodeoxycholic acid is also being investigated for use in several conditions such as Primary Biliary Cirrhosis (PBC), insulin resistance, amyloidosis, Cystic Fibrosis, Cholestasis, and Amyotrophic Lateral Sclerosis.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Cholagogues and Choleretics
Gastrointestinal agents that stimulate the flow of bile into the duodenum (cholagogues) or stimulate the production of bile by the liver (choleretic). (See all compounds classified as Cholagogues and Choleretics.)
Tauroursodeoxycholic acid is the more hydrophilic form of ursodeoxycholic acid, which is naturally produced in the body. In patients with properly functioning gallbladders, both of these bile acids inhibit liver cholesterol secretion and synthesis as well as intestinal cholesterol absorption allowing for the promotion of cholesterol gallstone dissolution. The mechanism of action of tauroursodeoxycholic acid in the other conditions is still being investigated.
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Announces Positive Phase 2 Results of AMX0035 For Wolfram Syndrome
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Pharmaceuticals Receives Orphan Drug Designation for AMX0035 in Wolfram Syndrome
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is a glutamine chelator small molecule drug candidate, being evaluated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 02, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (taurursodiol and sodium phenylbutyrate) is an oral small molecule drug candidate under evaluation for treating Wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Shares Interim Data from Phase 2 HELIOS Trial On AMX0035
Details : Relyvrio (taurursodiol and sodium phenylbutyrate) is an oral small molecule drug candidate under evaluation for treating Wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication for ALS, with FDA and Health Canada discussions for voluntary discontinuation of marketing authorizations.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx to Pull Failed ALS Drug Relyvrio From Market, cut 70% of Staffers
Details : Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication for ALS, with FDA and Health Canada discussions for voluntary discontinuation of marketing authorizations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (sodium phenylbutyrate and taurursodiol) is a specially formulated oral fixed-dose combination, which is being evaluated for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Reveals Topline Results from Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Details : Relyvrio (sodium phenylbutyrate and taurursodiol) is a specially formulated oral fixed-dose combination, which is being evaluated for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral, fixed-dose combination. It is a HDAC inhibitor which is being evaluated in phase 2 clinical trials for the treatment of Wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Completes Enrollment in HELIOS, Phase 2 Study of AMX0035 for Wolfram Syndrome
Details : Relyvrio (sodium phenylbutyrate and taurursodiol) is an oral, fixed-dose combination. It is a HDAC inhibitor which is being evaluated in phase 2 clinical trials for the treatment of Wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Amylyx investigational product Relyvrio (sodium phenylbutyrate) with Taurursodiol, is an oral, fixed-dose combination therapy. It is being evaluated in the Phase III clinical trial studies with patient for the treatment of Progressive Supranuclear Palsy.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Amylyx investigational product Relyvrio (sodium phenylbutyrate) with Taurursodiol, is an oral, fixed-dose combination therapy. It is being evaluated in the Phase III clinical trial studies with patient for the treatment of Progressive Supranuclear Palsy.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name Albrioza, received negative opinion from CHMP, for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name Albrioza, received negative opinion from CHMP, for the treatment of amyotrophic lateral sclerosis (ALS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Albrioza (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) currently being indicated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
Details : Albrioza (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) currently being indicated for the treatment of amyotrophic lateral sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Albrioza (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) currently being investigated for the treatment of wolfram syndrome.
Lead Product(s): Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 23, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sodium Phenylbutyrate,Tauroursodeoxycholic Acid
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Albrioza (sodium phenylbutyrate and taurursodiol) is an oral fixed-dose medication approved with conditions to treat amyotrophic lateral sclerosis (ALS) currently being investigated for the treatment of wolfram syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 23, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
ANALYTICAL
ABOUT THIS PAGE
94
PharmaCompass offers a list of Tauroursodeoxycholic Acid API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tauroursodeoxycholic Acid manufacturer or Tauroursodeoxycholic Acid supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tauroursodeoxycholic Acid manufacturer or Tauroursodeoxycholic Acid supplier.
PharmaCompass also assists you with knowing the Tauroursodeoxycholic Acid API Price utilized in the formulation of products. Tauroursodeoxycholic Acid API Price is not always fixed or binding as the Tauroursodeoxycholic Acid Price is obtained through a variety of data sources. The Tauroursodeoxycholic Acid Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Taurursodiol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Taurursodiol, including repackagers and relabelers. The FDA regulates Taurursodiol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Taurursodiol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Taurursodiol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Taurursodiol supplier is an individual or a company that provides Taurursodiol active pharmaceutical ingredient (API) or Taurursodiol finished formulations upon request. The Taurursodiol suppliers may include Taurursodiol API manufacturers, exporters, distributors and traders.
click here to find a list of Taurursodiol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Taurursodiol DMF (Drug Master File) is a document detailing the whole manufacturing process of Taurursodiol active pharmaceutical ingredient (API) in detail. Different forms of Taurursodiol DMFs exist exist since differing nations have different regulations, such as Taurursodiol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Taurursodiol DMF submitted to regulatory agencies in the US is known as a USDMF. Taurursodiol USDMF includes data on Taurursodiol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Taurursodiol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Taurursodiol suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Taurursodiol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Taurursodiol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Taurursodiol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Taurursodiol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Taurursodiol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Taurursodiol suppliers with NDC on PharmaCompass.
Taurursodiol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Taurursodiol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Taurursodiol GMP manufacturer or Taurursodiol GMP API supplier for your needs.
A Taurursodiol CoA (Certificate of Analysis) is a formal document that attests to Taurursodiol's compliance with Taurursodiol specifications and serves as a tool for batch-level quality control.
Taurursodiol CoA mostly includes findings from lab analyses of a specific batch. For each Taurursodiol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Taurursodiol may be tested according to a variety of international standards, such as European Pharmacopoeia (Taurursodiol EP), Taurursodiol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Taurursodiol USP).